In today’s Pharma Pulse, the FDA issues two high-stakes priority vouchers for cholesterol and cancer therapies, GSK leverages ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...

The about-$1 billion deal could come imminently.

The New Year's Champagne turned flat for Madrigal Pharmaceuticals ( MDGL 5.01%) on Tuesday. Investors traded out of the ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Nanoparticle technology offers significant market opportunities in pharmaceuticals and biomedicine, enhancing drug delivery, solubility, and targeted therapy. This field supports advancements in ...

Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines.

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

The Ministry of Public Health (MoPH) affirmed its commitment to supporting the national pharmaceutical industry in a way that meets local needs and meets th ...